{"filing":{"accession_number":"0001104659-26-066062","cik":"0001819411","ticker":"GANX","company_name":"Gain Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"tm2615594d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1819411/000110465926066062/tm2615594d1_8k.htm"},"events":[{"id":8958,"run_id":7864,"accession_number":"0001104659-26-066062","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"This disclosure reports interim clinical and biomarker data from a Phase 1b extension study of GT-02287 for Parkinson's disease, including safety, tolerability, and efficacy endpoints (GluSph reduction of 81%, stable MDS-UPDRS scores, and perceived clinical benefits). While this is a material clinical development update that would affect investor assessment of the drug candidate's progress, it does not fit neatly into the predefined taxonomy—it is neither an earnings release, M\u0026A activity, executive change, nor a negative event like restatement or going concern. The disclosure is material because clinical trial progress is central to a biopharmaceutical company's value proposition.","company_name":"Gain Therapeutics, Inc.","ticker":"GANX","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":[{"id":1420,"accession_number":"0001104659-26-066062","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"This disclosure reports interim clinical and biomarker data from a Phase 1b extension study of GT-02287 for Parkinson's disease, including safety, tolerability, and efficacy endpoints (GluSph reduction of 81%, stable MDS-UPDRS scores, and perceived clinical benefits). While this is a material clinical development update that would affect investor assessment of the drug candidate's progress, it does not fit neatly into the predefined taxonomy—it is neither an earnings release, M\u0026A activity, executive change, nor a negative event like restatement or going concern. The disclosure is material because clinical trial progress is central to a biopharmaceutical company's value proposition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:07:27.647938+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1420,"accession_number":"0001104659-26-066062","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"This disclosure reports interim clinical and biomarker data from a Phase 1b extension study of GT-02287 for Parkinson's disease, including safety, tolerability, and efficacy endpoints (GluSph reduction of 81%, stable MDS-UPDRS scores, and perceived clinical benefits). While this is a material clinical development update that would affect investor assessment of the drug candidate's progress, it does not fit neatly into the predefined taxonomy—it is neither an earnings release, M\u0026A activity, executive change, nor a negative event like restatement or going concern. The disclosure is material because clinical trial progress is central to a biopharmaceutical company's value proposition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:07:27.647938+00:00","company_name":"Gain Therapeutics, Inc.","ticker":"GANX","filing_date":"2026-05-26"}]}